Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Tel Aviv
Ofer Merimsky
41 years of experience
accreditations :
Clinic is certified :
Leiomyosarkoma treatment cost in Israel typically involves specialized diagnostics like histopathology revision ranging from $500 to $800. Total expenses depend on the tumor stage and surgical complexity, with savings of 30–80% compared to the United States. Key treatment centers are primarily located in Tel Aviv, Jerusalem, and Haifa, offering multidisciplinary care for rare soft-tissue sarcomas.
Typical Leiomyosarkoma Treatment Costs in Israel
Bookimed Expert Insight: For complex soft-tissue sarcomas, patients benefit most from centers with dedicated sarcoma units. Sourasky Medical Center (Ichilov) features Israel's only specialized sarcoma center led by experts like Professor Ofer Merimsky. Facilities with JCI accreditation and Newsweek rankings, such as Hadassah and Rambam, offer high-value care for rare diseases. These centers utilize robotic surgery and AI-driven imaging to maintain a 90% oncology success rate.
| Israel | Turkey | Austria | |
| Proton-beam therapy | from $48,000 | from $70,000 | from $80,000 |
| High intensity focused ultrasound ablation (HIFU) | from $15,200 | from $4,000 | from $12,000 |
| CyberKnife | from $17,500 | from $4,750 | from $50,000 |
| Chemotherapy for breast cancer | from $22,500 | from $1,200 | from $15,000 |
| Radiation therapy for colorectal cancer | - | from $7,000 | from $12,000 |
Prof. Ofer Merimsky leads the Soft Tissue and Bone Oncology Unit at Sourasky Medical Center – with specialized expertise in sarcoma treatment.
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Dr. Levin leads the pediatric sarcoma program at Sourasky Medical Center and studied at Italy's world-leading Rizzoli Orthopaedic Institute.
Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.
He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.
Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.
Israel is safe and highly effective for international leiomyosarcoma treatment. Its major oncology centers maintain Joint Commission International (JCI) accreditation. Specialized sarcoma units like those at Sourasky Medical Center report an average 90% success rate in oncology treatment within secure clinical environments.
Bookimed Expert Insight: Israeli oncology excels because surgeons such as Dr. Yuri Goldes and Dr. Zohar Dotan often hold specialized PhDs alongside clinical degrees. This dual expertise allows them to apply molecular and genetic tumor profiling directly to surgical strategy. At Sheba Medical Center, this leads to first-in-country robotic resections that prioritize preserving healthy tissue.
Patient Consensus: Patients note that verifying the diagnosis through histopathology revision in Israel is essential. They emphasize that coordinating the transfer of medical samples quickly is as vital as the surgery itself.
Curative-intent treatment for leiomyosarcoma in Israel achieves high success through specialized sarcoma centers. Sourasky Medical Center reports a 90% average success rate for oncology. Advanced centers like Hadassah and Assuta utilize Joint Commission International accreditation standards to ensure precise surgical and systemic outcomes.
Bookimed Expert Insight: Israeli oncology is defined by high-volume efficiency and specialized leadership. Sourasky Medical Center alone treats over 1,800,000 patients annually. Dr. Ofer Merimsky is the President of the Society of oncologists and radiotherapists Israel. This concentration of expertise in one facility often leads to more accurate initial staging. Our data shows that high patient volumes in centers like Hadassah correlate with faster access to multidisciplinary tumor boards.
Patient Consensus: Patients note that getting a second opinion on pathology slides in Israel is a vital step. They emphasize that identifying the correct sarcoma subtype changed their entire treatment plan.
Israel provides advanced leiomyosarcoma care through dedicated sarcoma units using precision radiation and robotic surgery. Specialized centers utilize CyberKnife radiosurgery and grid therapy for aggressive tumors. Leading experts like Dr. Dan Grisaro and Prof. Ofer Merimsky focus on multidisciplinary strategies for uterine and soft tissue cases.
Bookimed Expert Insight: While many oncology centers offer standard radiation, Israel hosts a dedicated sarcoma unit at Tel Aviv Sourasky Medical Center. This center is the only one in the region combining specialized surgical oncology with 3D-navigated resection. This allows for higher precision in tumor removal while preserving nearby healthy tissue function.
Patient Consensus: Patients note the relief of having a multidisciplinary team where oncologists and surgeons review scans together. They often highlight that coordinated care for rare sarcomas makes the complex travel logistics feel manageable.
Medical tourists typically spend 14 to 21 days in Israel for Leiomyosarcoma (LMS) evaluation and first-line treatment. This window covers an intensive 3–4 day diagnostic phase and approximately two weeks for initial therapeutic intervention. High-volume centers like Sourasky Medical Center report a 90% oncology success rate with streamlined protocols.
Bookimed Expert Insight: Israeli oncology centers like Assuta or Hadassah manage nearly 1,000,000 patients annually. This massive volume allows them to keep pathology labs open for international cases overnight. You can often get a second opinion on biopsy slides while your PET-CT is still being processed. This saves roughly 5 days compared to many European clinics.
Patient Consensus: Patients note it is essential to stay near the hospital for the first week after discharge. Many emphasize that having a local coordinator handle the rapid diagnostic appointments reduced their stress significantly during the first few days.
Good candidates for limb-preserving surgery possess intact neurovascular structures and sufficient soft tissue to maintain limb viability. Ideal robotic surgery candidates require high-precision tumor resections in complex anatomical areas. Israeli centers utilize robotic-assisted platforms to remove leiomyosarcoma volumes while sparing healthy bone and muscle tissue.
Bookimed Expert Insight: Israeli institutions like Sourasky Medical Center report a 90% average oncology success rate. Their use of robotic platforms often targets complex musculoskeletal resections. Coordination through multi-specialty teams in Jerusalem and Tel Aviv ensures that surgeons prioritize limb function over amputation whenever neurovascular bundles remain uninvolved.
Patient Consensus: Patients emphasize that preserving their natural limb significantly boosts their emotional well-being and long-term mobility. Many highlight that choosing surgeons at JCI-accredited facilities provides extra peace of mind during complex reconstructions.
Aftercare for leiomyosarcoma focuses on surgical site monitoring and managing systemic side effects from therapies like CyberKnife or proton-beam radiation. Patients transition to self-managed recovery within JCI-accredited facilities in Tel Aviv and Jerusalem. Success rates for oncology treatment at top institutions like Sourasky average 90%.
Bookimed Expert Insight: Israeli specialists like Dr. Ofer Merimsky often recommend a secondary histopathology revision even after treatment concludes. Data shows that precise diagnostic confirmation and ongoing consultations with radiologists ensure that follow-up imaging accurately distinguishes between scar tissue and potential new growth. This specialized oversight is a hallmark of the multi-disciplinary approach in Tel Aviv clinics.
Patient Consensus: Patients note that fatigue often lasts much longer than visible surgical healing. Many emphasize the importance of arranging physical therapy for lymphedema early and having a 24-hour contact number for medical questions after returning home.
Tel Aviv and Jerusalem are the primary Israeli hubs for leiomyosarcoma (LMS) treatment. Sourasky Medical Center houses the dedicated National Sarcoma Center. These facilities utilize multidisciplinary teams and advanced protocols like CyberKnife or genomic-guided therapies to manage rare smooth muscle cancers effectively.
Bookimed Expert Insight: Israeli oncology success often stems from diagnostic precision rather than just surgical skill. Our data shows that clinics like Sourasky achieve a 90% oncology success rate partly through mandatory histopathology revisions. Patients frequently discover their initial diagnosis was incorrect after Israeli specialists re-examine biopsy samples, which fundamentally changes the treatment protocol for rare cancers like LMS.
Patient Consensus: Patients emphasize that for rare cancers like leiomyosarcoma, it is vital to prioritize centers with high case volumes over convenient locations. Many find that getting a second opinion in Israel on biopsy slides is a crucial step for confirming the correct diagnosis.